Please login to the form below

Not currently logged in
Email:
Password:

US regulatory science awards announced

The US National Institutes of Health and the US Food and Drug Administration will partner on a scheme to award research projects in regulatory science

The US National Institutes of Health (NIH) and the US Food and Drug Administration (FDA) will partner on a scheme to award four research projects in regulatory science.

The NIH will award $9.4m over three years to projects which "better inform scientists and regulatory reviewers alike about medical product safety, and improve the evaluation and availability of new medical products to the community." The FDA will contribute $950,000 to the scheme.

Projects set to be recipients of the award include research by Dr Dennis E Hourcade on nanoparticles and work by researchers at the University of Michigan into innovative clinical trial design.

The other two projects are the development of an innovative heart/lung model by Dr Donald E Ingber, Harvard University Medical School, to test drug safety, and MB Research Laboratories' novel strategy to predict eye irritation.

"These four projects were chosen among many applications because they were the most meritorious proposals for addressing high priority areas in cutting-edge biomedical research and regulatory science," said NIH director, Dr Francis S Collins.

He continued: "This partnership marks the beginning of our work with the FDA to use new scientific and technological tools to aid/enhance the review of new drugs and devices. It is one facet of our shared commitment to speed the delivery of new medical products to patients."

The awards continue a commitment from both agencies made in February 2010 to work together on important public health issues under the NIH-FDA Joint Leadership Council.

29th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics